A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents - Trial 2014-004993-40

Name: Clinical Trial 2014-004993-40
Creator: Merck & Co., Inc.
Keywords: Type 2 Diabetes Mellitus, clinical trial

Access comprehensive clinical trial information for 2014-004993-40 through Pure Global AI's free database. This phase not specified trial is sponsored by Merck & Co., Inc. and is currently status unknown. The study focuses on Type 2 Diabetes Mellitus.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to EU Clinical Trials Register data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database

840K+ Trials

2014-004993-40

Trial Details

EU Clinical Trials Register • 2014-004993-40

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing

A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents

Study Focus

Disease/Condition

Type 2 Diabetes Mellitus

Sponsor & Location

Primary Sponsor

Merck & Co., Inc.

Timeline & Enrollment

Phase

N/A

Start Date

N/A

End Date

N/A

Primary Outcome

•Number of participants who experienced at least one adverse event pre-study through 10 to 14 days following administration of study drug.

ICD-10 Classifications

Type 2 diabetes mellitus

Type 2 diabetes mellitus with unspecified complications

Type 2 diabetes mellitus with other specified complications

Type 2 diabetes mellitus without complications

Type 2 diabetes mellitus with multiple complications

Data Source

Registry

EU Clinical Trials Register

Trial ID

2014-004993-40

Type

Non-Device Trial